Assessing recent moves in Reinsurance Group of America (RGA)

Reinsurance Group of America (RGA) has come under closer investor scrutiny after a recent pullback, with the share price down about 11% over the past month and modestly lower over the past 3 months.

This softer near term performance contrasts with a 5.1% total return over the past year and stronger multi year results. This has prompted investors to reassess how RGA’s valuation lines up with its earnings profile and reinsurance focused business mix.

The recent 11% one-month share price decline, alongside a softer three-month share price return, sits against a longer track record where total shareholder returns over three and five years have been much stronger. This suggests recent momentum is fading compared with the longer-term trend and may reflect investors reassessing growth prospects or risk around the current US$197.99 share price.

If this pullback has you rethinking your portfolio mix, it could be a good moment to broaden your search and check out 20 top founder-led companies

So, with RGA posting multi year total returns above 60%, annual revenue of about US$23.7b and net income of US$1.2b, alongside a recent 11% pullback, is this weakness a buying opportunity or is the market already pricing in future growth?

Most Popular Narrative: 20.7% Undervalued

Analysts currently frame Reinsurance Group of America as undervalued, with a fair value estimate of about $249.56 versus the recent $197.99 share price, and that gap is built on specific growth, margin and capital deployment assumptions.

Recent material improvements in deployable and excess capital, enabled by new in-force value credits and a strong balance sheet, provide RGA with the flexibility to pursue high-return new business, return capital to shareholders via buybacks/dividends, and deploy capital for select accretive acquisitions, all supporting future EPS and ROE uplift.

Analysts are not just plugging in generic growth rates. They are baking in a very specific path for revenue, profitability, and share count that underpins this fair value gap. Want to see which assumptions really move the needle on that $249.56 figure and how they connect to future earnings power and capital returns?

Result: Fair Value of $249.56 (UNDERVALUED)

However, there are real swing factors here, including earnings volatility in US life and healthcare excess lines, as well as the risk that rising medical costs squeeze future margins.

Next Steps

If this mix of recent weakness and longer term strength leaves you unsure, take a closer look at the facts, act while sentiment is still shifting, and review the 5 key rewards

Looking for more investment ideas?

If RGA has sharpened your focus, do not stop here; use the Simply Wall St screener to uncover other opportunities that could fit your goals and risk comfort.

• Target potential value opportunities by scanning 52 high quality undervalued stocks that pair strong fundamentals with prices that may not fully reflect their underlying numbers.
• Build a steadier income stream by reviewing 13 dividend fortresses that focus on higher yields with an emphasis on resilience.
• Prioritise capital preservation by checking 68 resilient stocks with low risk scores designed to highlight companies with more defensive risk profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.